Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pankaj Mathur

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Antioxidants & Redox Signaling|May 21, 2016
Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in ApoptosisZufeng Ding, Shijie Liu, Xianwei Wang, et al.
Expert Review of Cardiovascular Therapy|November 23, 2017
Cardiovascular complications of multiple myeloma in the elderlyPankaj Mathur, Sharmilan Thanendrarajan, Hakan Paydak, et al.
Immunotherapy|February 19, 2016
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Sharmilan Thanendrarajan, Faith E Davies, Gareth J Morgan, et al.
Haematologica|August 12, 2021
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease statusDavid Baker, Milan Bimali, Luis Carrillo, et al.
Haematologica|December 1, 2021
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease statusDavid Baker, Milan Bimali, Luis Carrillo, et al.
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Journal of Clinical Medicine|March 25, 2022
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital AdmissionKristin Larsen, Horace Spencer, Meera Mohan, et al.
Haematologica|May 20, 2017
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtypeCarolina Schinke, Antje Hoering, Hongwei Wang, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Antioxidants & Redox Signaling|May 21, 2016
Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in ApoptosisZufeng Ding, Shijie Liu, Xianwei Wang, et al.
Expert Review of Cardiovascular Therapy|November 23, 2017
Cardiovascular complications of multiple myeloma in the elderlyPankaj Mathur, Sharmilan Thanendrarajan, Hakan Paydak, et al.
Immunotherapy|February 19, 2016
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Sharmilan Thanendrarajan, Faith E Davies, Gareth J Morgan, et al.
Haematologica|August 12, 2021
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease statusDavid Baker, Milan Bimali, Luis Carrillo, et al.
Haematologica|December 1, 2021
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease statusDavid Baker, Milan Bimali, Luis Carrillo, et al.
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Journal of Clinical Medicine|March 25, 2022
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital AdmissionKristin Larsen, Horace Spencer, Meera Mohan, et al.
Haematologica|May 20, 2017
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtypeCarolina Schinke, Antje Hoering, Hongwei Wang, et al.
Pageof 3